Valuation: Mendus AB

Market Cap 429M 44.83M 38.86M 36.43M 33.21M 62.49M 4.28B 63.5M 167M 2.14B 168M 165M 7.14B P/E 2026 *
-4.45x
P/E 2027 * -5.79x
Enterprise Value 108M 11.25M 9.75M 9.14M 8.33M 15.68M 1.07B 15.93M 42.01M 537M 42.22M 41.31M 1.79B EV / Sales 2026 *
18x
EV / Sales 2027 * 1.55x
Free-Float
34.33%
Yield 2026 *
-
Yield 2027 * -
1 day+1.20%
1 week-3.03%
Current month-3.03%
1 month+5.82%
3 months+12.54%
6 months+39.63%
Current year+20.18%
1 week 6.4
Extreme 6.4
6.96
1 month 6
Extreme 6
6.96
Current year 3.86
Extreme 3.86
7.49
1 year 3.86
Extreme 3.86
9.37
3 years 3.86
Extreme 3.86
16.38
5 years 3.86
Extreme 3.86
126.8
10 years 3.86
Extreme 3.86
640
Manager TitleAgeSince
Chief Executive Officer 54 2021-03-15
Chief Executive Officer 76 2019-12-12
Director of Finance/CFO 60 2021-02-27
Director TitleAgeSince
Chairman 52 2021-01-21
Director/Board Member 64 2019-12-31
Director/Board Member 74 2012-12-31
Date Insider Type Main position Quantity % Market Cap.
2/28/22 Buy

Chief Technology Officer

10,000 0.0050%
2/24/22 Buy

Chief Financial Officer

10,000 0.0050%
2/24/22 Buy

Chief Financial Officer

10,000 0.0050%
Change 5-day change 1-year change 3-year change Capi.($)
+1.20%-3.03%-13.72%-5.34% 44.39M
+1.17%+1.09%+4.03%+15.74% 48.72B
-1.59%+2.12%+460.02%+573.56% 43.99B
-0.85%+7.95%+15.77%+80.09% 40.82B
-0.08%+3.91%+26.96%+9.86% 39.79B
0.00%+3.59%+20.51%+48.00% 32.7B
-2.52%-0.52%+24.35%+118.05% 16.66B
-3.61%-1.45% - - 16.84B
+0.72%+0.31%+4.94%+21.70% 13.95B
-1.09%+5.94%+81.46%+31.15% 13.58B
Average -0.66%+1.81%+69.37%+99.20% 26.71B
Weighted average by Cap. -0.59%+2.44%+97.51%+135.56%

Financials

2026 *2027 *
Net sales 5.97M 624K 541K 507K 462K 869K 59.52M 883K 2.33M 29.79M 2.34M 2.29M 99.39M 150M 15.64M 13.56M 12.71M 11.59M 21.81M 1.49B 22.16M 58.43M 747M 58.73M 57.46M 2.49B
Net income -150M -15.7M -13.61M -12.75M -11.63M -21.88M -1.5B -22.23M -58.63M -750M -58.93M -57.65M -2.5B -66.57M -6.96M -6.03M -5.65M -5.15M -9.7M -664M -9.85M -25.99M -332M -26.12M -25.56M -1.11B
Net Debt -321M -33.58M -29.11M -27.29M -24.88M -46.82M -3.21B -47.57M -125M -1.6B -126M -123M -5.35B -197M -20.59M -17.85M -16.73M -15.26M -28.71M -1.97B -29.16M -76.91M -984M -77.3M -75.63M -3.28B
Logo Mendus AB
Mendus AB (publ), formerly Immunicum AB, is a Sweden-based company that is engaged in the biopharmaceutical sector. The Company develops immunotherapy for therapeutic treatment of cancer and infectious diseases. The Company develops off-the-shelf, cell-based products that are immunogenic based on underlying allogeneic dendritic cell biology and which have the potential to activate the patient’s own immune system against cancer. The Company’s programs ilixadencel and DCP-001 are derived from healthy donor material and from Company's DCOne cell line, respectively. The Company develops ilixadencel to address the tumor burden of established tumors via intratumoral immune priming and DCP-001 as a cancer relapse vaccine, aimed at the reduction of tumor recurrence following initial treatment. Mendus has offices in Sweden and the Netherlands.
Employees
19
Date Price Change Volume
26-08-13 SEK 6.730 +1.20% 21,041
26-08-12 SEK 6.650 +2.62% 20,935
26-08-11 SEK 6.480 -3.57% 24,774
26-08-10 SEK 6.720 -1.90% 13,144
26-08-07 SEK 6.850 -1.30% 8,779
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
6.730SEK
Average target price
33.00SEK
Spread / Average Target
+390.34%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IMMU Stock